The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.
Open accessAbstract
Although past reports have identified a variety of prognostic factors in patients with severe chronic heart failure, previous studies have not evaluated the interaction of prognostic variables and drug treatment. We analyzed the association of 30 clinical, hemodynamic, and biochemical variables with survival in 203 consecutive patients with severe heart failure; all variables were assessed just before initiation of treatment with a variety of vasodilator drugs, and all patients were subsequently followed for 6 to 94 months. By regression analysis, pretreatment serum sodium concentration was the most powerful predictor of cardiovascular mortality, with hyponatremic patients having a substantially shorter median survival than did patients with a normal serum sodium concentration (164 vs 373 days, p = .006). The unfavorable prognosis for hyponatremic patients appeared to be related to the marked elevation of plasma renin activity that we noted in these individuals (10.0 +/- 2.0 ng/ml/hr), since hyponatremic patients fared significantly better when treated with angiotensin converting-enzyme inhibitors than when treated with vasodilator drugs that did not interfere with angiotensin II biosynthesis (median survival 232 vs 108 days, p = .003). In contrast, there was no selective benefit of converting-enzyme inhibition on the survival of patients with a normal serum sodium concentration, in whom plasma renin activity was low (1.9 +/- 0.3 ng/ml/hr). This interaction between serum sodium concentration, drug treatment, and long-term outcome suggests that the renin-angiotensin system may exert a deleterious effect on the survival of some patients with chronic heart failure, which can be antagonized by converting enzyme inhibition, and provides a clinical counterpart for the similar prognostic role that has been postulated for angiotensin II in experimental preparations of heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B., & Rector, T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409273111303 · Cited by 3,125
Hypokalemia from Beta 2 -Receptor Stimulation by Circulating Epinephrine
Brown, M. J., Brown, D. C., & Murphy, M. B. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312083092303 · Cited by 644
Antidiuretic hormone in congestive heart failure.
Riegger, G. A. J., Liebau, G., & Kochsiek, K. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90576-9 · Cited by 193
Cited by
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582
Self-citationTolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Epidemiology, pathophysiology, and management of hyponatremic encephalopathy.
Fraser, C. L., & Arieff, A. I. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00274-4 · Cited by 288
Causes and treatment of oedema in patients with heart failure
Clark, A. L., & Cleland, J. G. F. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.191 · Cited by 112
Krack, A., Richartz, B. M., Gastmann, A., Greim, K., Lotze, U., Anker, S. D., & Figulla, H. R. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.03.002 · Cited by 83
Metadata
- Authors
- Lee, W. H., & Packer, M.
- Venue
- Circulation
- Published
- 1986-02
- Volume
- 73
- Issue
- 2
- Pages
- 257-267
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2074330505
- Cited by
- 552
- References
- 3
- FWCI
- 17.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
